Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma

Joseph Alcalay, Gil Tauber, Eyal Fenig, Emmilia Hodak

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Background: Vismodegib, a hedgehog pathway inhibitor has been recently introduced as an oral therapy for locally advanced and metastatic basal cell carcinoma. Although treatment of patients with basal cell carcinoma with vismodegib has been associated with partial or complete clinical response, it is still unclear if it is also associated with histological cure. Patients: Two patients with 3 large and aggressive basal cell carcinomas were treated with Vismodegib for 6 months. The treatment was followed by Mohs micrographic surgery. Results: Two tumors disappeared clinically and one was reduced dramatically in its size following treatment with vismodegib. Mohs surgery in all three tumors revealed residual islands of BCC although margins were cleared at the end of surgery. Conclusions: Neoadjuvant therapy with vismodegib for 6 months prior to Mohs surgery was effective in reducing the size of primary and recurrent aggressive basal cell carcinoma. However, residual tumor nests were found during surgery. Further larger studies are needed to evaluate the efficacy of Vismodegib as a neoadjuvant treatment prior to Mohs surgery.

Original languageEnglish
Pages (from-to)219-221
Number of pages3
JournalJournal of Drugs in Dermatology
Issue number3
StatePublished - 1 Mar 2015


Dive into the research topics of 'Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma'. Together they form a unique fingerprint.

Cite this